

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:43
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

F1_Rev.1_M3

NTP Study Number: C20209
Lock Date: 08/31/2011
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.2_002
PWG Approval Date: NONE

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
------------------	---------	---------	----------	-----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Dosing Accident	1			2
Moribund Sacrifice	15	7	14	36
Natural Death	5	10	5	12
Survivors				
Terminal Sacrifice	29	33	31	
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Foreign Body				1 (2%)
Inflammation, Acute	1 (2%)			2 (4%)
Inflammation, Chronic		1 (2%)		
Mineralization	1 (2%)			
Necrosis	1 (2%)			2 (4%)
Muscularis, Degeneration		2 (4%)	2 (4%)	
Gallbladder	(43)	(42)	(41)	(31)
Cyst			1 (2%)	
Intestine Large, Cecum	(46)	(43)	(45)	(45)
Lymphoid Tissue, Necrosis	1 (2%)			
Intestine Large, Colon	(48)	(44)	(46)	(46)
Intestine Large, Rectum	(48)	(46)	(46)	(46)
Serosa, Fibrosis		1 (2%)		
Intestine Small, Duodenum	(46)	(43)	(47)	(44)
Infiltration Cellular, Plasma Cell			1 (2%)	
Inflammation			1 (2%)	
Intestine Small, Ileum	(45)	(41)	(44)	(43)
Intestine Small, Jejunum	(46)	(42)	(44)	(46)
Peyer's Patch, Hyperplasia		1 (2%)		
Serosa, Fibrosis				1 (2%)
Liver	(50)	(50)	(50)	(50)
Angiectasis			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Basophilic Focus	6 (12%)	2 (4%)		5 (10%)
Basophilic Focus, Multiple		1 (2%)	1 (2%)	
Clear Cell Focus	10 (20%)	6 (12%)	17 (34%)	7 (14%)
Clear Cell Focus, Multiple		7 (14%)	3 (6%)	
Congestion		1 (2%)		
Depletion Glycogen	1 (2%)	1 (2%)		
Eosinophilic Focus	14 (28%)	12 (24%)	4 (8%)	10 (20%)
Eosinophilic Focus, Multiple	1 (2%)	10 (20%)	6 (12%)	1 (2%)
Fatty Change	17 (34%)	25 (50%)	17 (34%)	5 (10%)
Hematopoietic Cell Proliferation	10 (20%)	5 (10%)	1 (2%)	3 (6%)
Hemorrhage	3 (6%)	1 (2%)	1 (2%)	2 (4%)
Inflammation, Chronic	13 (26%)	19 (38%)	22 (44%)	12 (24%)
Mineralization	1 (2%)			
Mixed Cell Focus	2 (4%)	4 (8%)		1 (2%)
Mixed Cell Focus, Multiple		1 (2%)		
Necrosis, Focal	2 (4%)	2 (4%)	16 (32%)	2 (4%)
Tension Lipidosis	1 (2%)			
Bile Duct, Cyst	1 (2%)			
Centrilobular, Hepatocyte, Hypertrophy		28 (56%)	46 (92%)	48 (96%)
Hepatocyte, Mitotic Alteration		1 (2%)		
Hepatocyte, Necrosis				1 (2%)
Kupffer Cell, Pigmentation	5 (10%)	15 (30%)	33 (66%)	25 (50%)
Mesentery	(12)	(3)	(9)	(5)
Hemorrhage	1 (8%)			
Inflammation, Chronic	1 (8%)			1 (20%)
Artery, Inflammation, Chronic Active			2 (22%)	2 (40%)
Artery, Thrombosis	1 (8%)			
Fat, Necrosis	8 (67%)	3 (100%)	6 (67%)	2 (40%)
Pancreas	(50)	(50)	(50)	(50)
Atrophy	10 (20%)	14 (28%)	7 (14%)	
Cyst	1 (2%)	4 (8%)		
Degeneration				1 (2%)
Hemorrhage				1 (2%)
Hypertrophy, Focal	1 (2%)			
Inflammation, Granulomatous, Focal		1 (2%)		
Inflammation, Acute		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Inflammation, Chronic	12 (24%)	17 (34%)	19 (38%)	8 (16%)
Inflammation, Chronic Active	2 (4%)			
Mineralization		2 (4%)		
Necrosis		2 (4%)		
Acinus, Hyperplasia, Focal			1 (2%)	
Artery, Inflammation, Chronic Active		1 (2%)		
Artery, Mineralization		1 (2%)		
Artery, Necrosis		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy	2 (4%)			
Cyst	1 (2%)			
Hyperplasia, Lymphoid				1 (2%)
Infiltration Cellular, Mononuclear Cell	31 (62%)	38 (76%)	30 (60%)	21 (42%)
Inflammation, Granulomatous	1 (2%)			
Inflammation, Acute		1 (2%)		
Mineralization		5 (10%)	4 (8%)	1 (2%)
Necrosis		1 (2%)		
Vacuolization Cytoplasmic, Macrovesicular		1 (2%)		
Stomach, Forestomach	(50)	(50)	(50)	(50)
Cyst		1 (2%)		
Edema			2 (4%)	
Erosion	4 (8%)	5 (10%)	9 (18%)	3 (6%)
Fibrosis	2 (4%)			
Foreign Body			2 (4%)	
Inflammation	18 (36%)	18 (36%)	34 (68%)	19 (38%)
Mineralization	1 (2%)			1 (2%)
Necrosis	1 (2%)		1 (2%)	
Ulcer	9 (18%)	8 (16%)	14 (28%)	11 (22%)
Epithelium, Hyperplasia	26 (52%)	19 (38%)	40 (80%)	29 (58%)
Serosa, Fibrosis			1 (2%)	
Stomach, Glandular	(50)	(48)	(48)	(50)
Dilatation			1 (2%)	
Edema			1 (2%)	
Erosion			1 (2%)	2 (4%)
Fibrosis		1 (2%)		
Hemorrhage				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Inflammation	1 (2%)	1 (2%)	2 (4%)	
Inflammation, Acute	1 (2%)	1 (2%)		
Mineralization	4 (8%)	5 (10%)	6 (13%)	2 (4%)
Necrosis			1 (2%)	
Ulcer	1 (2%)		2 (4%)	1 (2%)
Glands, Ectasia, Focal		1 (2%)	2 (4%)	
Serosa, Fibrosis			1 (2%)	
Tongue	(0)	(0)	(0)	(1)
Angiectasis				1 (100%)
Tooth	(2)	(1)	(0)	(1)
Inflammation, Acute	1 (50%)			1 (100%)
Inflammation, Chronic Active	1 (50%)			
Malformation		1 (100%)		
Necrosis	1 (50%)			

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(49)	(50)	(50)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	8 (16%)	10 (20%)	7 (14%)	1 (2%)
Inflammation, Acute		1 (2%)		
Mineralization	1 (2%)		5 (10%)	5 (10%)
Thrombosis		1 (2%)		
Artery, Inflammation, Chronic Active	1 (2%)			
Artery, Mineralization			1 (2%)	

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(49)	(48)
Accessory Adrenal Cortical Nodule	2 (4%)	2 (4%)	7 (14%)	1 (2%)
Degeneration, Fatty	1 (2%)		1 (2%)	2 (4%)
Hyperplasia			1 (2%)	
Hypertrophy, Focal	10 (20%)	10 (20%)	5 (10%)	3 (6%)
Hypertrophy, Diffuse	1 (2%)		3 (6%)	20 (42%)
Vacuolization Cytoplasmic	1 (2%)		1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Capsule, Fibrosis				1 (2%)
Capsule, Hemorrhage				1 (2%)
Capsule, Hyperplasia	42 (84%)	41 (82%)	47 (96%)	41 (85%)
Adrenal Medulla	(50)	(50)	(50)	(48)
Hyperplasia		1 (2%)		1 (2%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	32 (64%)	25 (50%)	21 (42%)	6 (12%)
Parathyroid Gland	(48)	(43)	(49)	(44)
Cyst	3 (6%)	1 (2%)	5 (10%)	
Pituitary Gland	(47)	(43)	(43)	(44)
Pars Distalis, Angiectasis	1 (2%)			
Pars Distalis, Cyst	2 (4%)	2 (5%)		1 (2%)
Pars Distalis, Hyperplasia, Focal		1 (2%)	4 (9%)	1 (2%)
Thyroid Gland	(50)	(49)	(50)	(49)
Hypertrophy		1 (2%)		
Mineralization	1 (2%)			
C-cell, Hyperplasia			1 (2%)	
Follicle, Cyst			1 (2%)	1 (2%)
Follicle, Degeneration	21 (42%)	19 (39%)	12 (24%)	6 (12%)
Follicle, Degeneration, Focal		1 (2%)		
Follicle, Hypertrophy	25 (50%)	35 (71%)	41 (82%)	45 (92%)

GENERAL BODY SYSTEM

Tissue NOS	(2)	(1)	(0)	(1)
Abdominal, Fibrosis		1 (100%)		
Fat, Necrosis		1 (100%)		

GENITAL SYSTEM

Coagulating Gland	(1)	(0)	(1)	(0)
Cyst	1 (100%)			
Epididymis	(50)	(50)	(50)	(50)
Fibrosis				1 (2%)
Granuloma Sperm	1 (2%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Inflammation, Granulomatous	1 (2%)			
Inflammation, Chronic	21 (42%)	28 (56%)	24 (48%)	7 (14%)
Inflammation, Chronic Active	1 (2%)			
Necrosis	1 (2%)			
Artery, Inflammation	1 (2%)			
Penis	(1)	(0)	(1)	(0)
Concretion	1 (100%)			
Inflammation, Acute	1 (100%)			
Preputial Gland	(50)	(50)	(50)	(50)
Cyst	9 (18%)	16 (32%)	14 (28%)	3 (6%)
Ectasia		1 (2%)		
Fibrosis		1 (2%)		
Inflammation, Acute	2 (4%)			1 (2%)
Inflammation, Chronic	24 (48%)	28 (56%)	25 (50%)	5 (10%)
Inflammation, Chronic Active	1 (2%)	1 (2%)	3 (6%)	
Necrosis			1 (2%)	
Prostate	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Fibrosis		1 (2%)		
Inflammation, Granulomatous				1 (2%)
Inflammation, Acute	4 (8%)	2 (4%)	1 (2%)	
Inflammation, Chronic	27 (54%)	33 (66%)	30 (60%)	15 (30%)
Inflammation, Chronic Active		1 (2%)		
Necrosis		1 (2%)		
Epithelium, Hyperplasia	3 (6%)		1 (2%)	
Seminal Vesicle	(50)	(50)	(49)	(49)
Atrophy			1 (2%)	
Dilatation		1 (2%)		
Hemorrhage		1 (2%)	1 (2%)	
Inflammation, Acute	2 (4%)	1 (2%)		
Inflammation, Chronic	3 (6%)	7 (14%)	8 (16%)	
Testes	(50)	(50)	(50)	(49)
Abnormal Residual Body		1 (2%)	1 (2%)	1 (2%)
Angiectasis				1 (2%)
Giant Cell	2 (4%)		4 (8%)	2 (4%)
Germinal Epithelium, Atrophy	11 (22%)	8 (16%)	20 (40%)	13 (27%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Myeloid Cell, Hyperplasia	2 (4%)			
Lymph Node	(5)	(4)	(4)	(1)
Hyperplasia, Lymphoid	1 (20%)			
Pigmentation	2 (40%)		2 (50%)	
Iliac, Hyperplasia, Lymphoid		1 (25%)		
Inguinal, Hyperplasia, Lymphoid				1 (100%)
Inguinal, Pigmentation			1 (25%)	
Lymph Node, Mandibular	(50)	(49)	(49)	(46)
Atrophy	1 (2%)		1 (2%)	
Hemorrhage	2 (4%)	3 (6%)		
Hyperplasia, Lymphoid		1 (2%)		
Hyperplasia, Plasma Cell	1 (2%)			
Infiltration Cellular, Polymorphonuclear	1 (2%)	1 (2%)		
Necrosis, Lymphoid	1 (2%)			
Pigmentation	45 (90%)	48 (98%)	46 (94%)	44 (96%)
Lymph Node, Mesenteric	(49)	(47)	(46)	(47)
Angiectasis			1 (2%)	
Atrophy				3 (6%)
Congestion	1 (2%)		3 (7%)	
Ectasia	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Hematopoietic Cell Proliferation	1 (2%)		1 (2%)	
Hemorrhage	3 (6%)	7 (15%)	7 (15%)	8 (17%)
Hyperplasia, Lymphoid	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Hyperplasia, Plasma Cell			1 (2%)	
Infiltration Cellular, Polymorphonuclear	1 (2%)	1 (2%)		1 (2%)
Necrosis, Lymphoid		1 (2%)		
Pigmentation	1 (2%)		2 (4%)	4 (9%)
Spleen	(50)	(47)	(47)	(47)
Atrophy	1 (2%)			
Hematopoietic Cell Proliferation	14 (28%)	10 (21%)	13 (28%)	25 (53%)
Infiltration Cellular, Eosinophil				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pigmentation	13 (26%)	12 (26%)	2 (4%)	2 (4%)
Capsule, Fibrosis, Focal		1 (2%)		
Capsule, Inflammation, Granulomatous, Focal		1 (2%)		
Lymphoid Follicle, Atrophy	1 (2%)	2 (4%)	3 (6%)	4 (9%)
Lymphoid Follicle, Hyperplasia	11 (22%)	7 (15%)	9 (19%)	5 (11%)
Thymus	(40)	(41)	(40)	(39)
Atrophy	26 (65%)	28 (68%)	23 (58%)	23 (59%)
Cyst	14 (35%)	12 (29%)	13 (33%)	3 (8%)
Hemorrhage				1 (3%)
Hyperplasia, Lymphoid	1 (3%)	2 (5%)	3 (8%)	1 (3%)
Infiltration Cellular, Histiocyte			1 (3%)	1 (3%)
Inflammation, Granulomatous, Focal			1 (3%)	
Necrosis, Lymphoid		6 (15%)	3 (8%)	3 (8%)

INTEGUMENTARY SYSTEM

Mammary Gland	(2)	(2)	(1)	(4)
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion			1 (2%)	
Fibrosis		1 (2%)		1 (2%)
Fibrosis, Focal			1 (2%)	
Foreign Body				1 (2%)
Hemorrhage				1 (2%)
Hyperkeratosis	1 (2%)	3 (6%)		1 (2%)
Inflammation, Acute	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Inflammation, Chronic	2 (4%)	3 (6%)		2 (4%)
Inflammation, Chronic Active	1 (2%)	1 (2%)		1 (2%)
Mineralization			2 (4%)	
Thrombosis				1 (2%)
Ulcer	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Epidermis, Hyperplasia	1 (2%)	1 (2%)		
Epidermis, Tail, Hyperplasia				2 (4%)
Lip, Inflammation, Acute	2 (4%)	1 (2%)		
Prepuce, Inflammation, Acute			2 (4%)	
Subcutaneous Tissue, Angiectasis, Focal		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Subcutaneous Tissue, Cyst			1 (2%)	
Subcutaneous Tissue, Inflammation, Chronic	1 (2%)			
Subcutaneous Tissue, Necrosis	1 (2%)			
MUSCULOSKELETAL SYSTEM				
Bone	(49)	(50)	(50)	(49)
Fibro-Osseous Lesion	2 (4%)	1 (2%)		
Tail, Callus		2 (4%)		1 (2%)
Tail, Developmental Malformation	1 (2%)	3 (6%)		
Vertebra, Callus	2 (4%)			
Skeletal Muscle	(2)	(2)	(0)	(0)
Fibrosis	2 (100%)			
Hemorrhage	2 (100%)			
Inflammation, Chronic	2 (100%)			
Regeneration	1 (50%)			
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion				1 (2%)
Hemorrhage	6 (12%)	2 (4%)	2 (4%)	5 (10%)
Infiltration Cellular, Mononuclear Cell		2 (4%)		
Inflammation, Acute				1 (2%)
Metaplasia, Osseous		1 (2%)		
Necrosis			1 (2%)	
Meninges, Inflammation, Acute		1 (2%)		
Meninges, Inflammation, Chronic	1 (2%)			
Meninges, Thrombosis		1 (2%)		
Peripheral Nerve	(2)	(1)	(1)	(0)
Degeneration	2 (100%)	1 (100%)	1 (100%)	
Hemorrhage	1 (50%)			
Spinal Cord	(1)	(1)	(1)	(0)
Degeneration			1 (100%)	
Hemorrhage			1 (100%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE

0 MG/KG

3 MG/KG

30 MG/KG

100 MG/KG

RESPIRATORY SYSTEM

	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung	(50)	(50)	(50)	(50)
Congestion	1 (2%)			2 (4%)
Fibrosis			1 (2%)	
Foreign Body				1 (2%)
Hemorrhage	10 (20%)	6 (12%)	6 (12%)	3 (6%)
Hyperplasia				1 (2%)
Infiltration Cellular, Histiocyte	8 (16%)	11 (22%)	5 (10%)	1 (2%)
Inflammation, Acute	2 (4%)	1 (2%)		1 (2%)
Inflammation, Chronic	1 (2%)			1 (2%)
Metaplasia, Osseous				1 (2%)
Mineralization	1 (2%)	2 (4%)	3 (6%)	2 (4%)
Thrombosis	3 (6%)			
Alveolar Epithelium, Hyperplasia	2 (4%)	6 (12%)	1 (2%)	
Alveolar Epithelium, Hypertrophy				1 (2%)
Alveolus, Infiltration Cellular, Histiocyte			1 (2%)	
Nose	(50)	(48)	(50)	(50)
Foreign Body	4 (8%)	7 (15%)	7 (14%)	5 (10%)
Fungus	1 (2%)		2 (4%)	
Hemorrhage			1 (2%)	
Inflammation, Acute	9 (18%)	12 (25%)	19 (38%)	6 (12%)
Mineralization	2 (4%)	2 (4%)	2 (4%)	
Glands, Fibrosis	1 (2%)			
Pleura	(0)	(1)	(0)	(0)
Trachea	(47)	(48)	(49)	(47)
Hemorrhage		1 (2%)		

SPECIAL SENSES SYSTEM

	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Eye	(49)	(47)	(47)	(46)
Atrophy	1 (2%)			
Cataract			1 (2%)	
Anterior Chamber, Edema	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Anterior Chamber, Infiltration Cellular, Polymorphonuclear	1 (2%)			
Anterior Chamber, Necrosis	1 (2%)			
Cornea, Fibrosis	1 (2%)			
Cornea, Inflammation	1 (2%)			
Cornea, Inflammation, Acute	1 (2%)		1 (2%)	
Cornea, Inflammation, Chronic Active	1 (2%)	1 (2%)		
Cornea, Necrosis	1 (2%)		1 (2%)	
Cornea, Epithelium, Hyperplasia	1 (2%)			
Nerve, Degeneration	1 (2%)			
Nerve, Inflammation, Acute	1 (2%)			
Retrobulbar, Inflammation, Acute			1 (2%)	
Harderian Gland	(50)	(49)	(50)	(50)
Atrophy	1 (2%)			
Fibrosis	1 (2%)			
Hemorrhage	1 (2%)			
Hyperplasia	1 (2%)	2 (4%)	1 (2%)	
Hyperplasia, Focal	1 (2%)			
Inflammation, Acute	1 (2%)			
Inflammation, Chronic	1 (2%)			
Necrosis	1 (2%)			
Zymbal's Gland	(1)	(0)	(0)	(0)

URINARY SYSTEM

Kidney	(50)	(50)	(49)	(50)
Casts Protein		1 (2%)		
Congestion	1 (2%)			
Hydronephrosis		1 (2%)		
Hyperplasia, Lymphoid		1 (2%)	1 (2%)	
Infarct	2 (4%)	1 (2%)	5 (10%)	
Infarct, Multiple	1 (2%)			
Infiltration Cellular, Mononuclear Cell	35 (70%)	41 (82%)	39 (80%)	26 (52%)
Inflammation			1 (2%)	
Inflammation, Acute	1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Metaplasia, Osseous	2 (4%)	2 (4%)	1 (2%)	
Mineralization	36 (72%)	32 (64%)	24 (49%)	6 (12%)
Nephropathy	38 (76%)	45 (90%)	37 (76%)	9 (18%)
Artery, Perirenal Tissue, Inflammation	1 (2%)			
Interstitialium, Inflammation	1 (2%)			
Interstitialium, Inflammation, Chronic	2 (4%)	1 (2%)	1 (2%)	
Papilla, Inflammation, Acute	1 (2%)	2 (4%)		
Papilla, Necrosis	4 (8%)	6 (12%)	2 (4%)	
Papilla, Pelvis, Inflammation, Acute			1 (2%)	
Papilla, Renal Tubule, Necrosis		1 (2%)		
Pelvis, Inflammation, Acute	1 (2%)			
Pelvis, Inflammation, Chronic	1 (2%)			
Renal Tubule, Cyst	1 (2%)	2 (4%)	1 (2%)	
Renal Tubule, Cyst, Multiple	1 (2%)			
Renal Tubule, Degeneration	3 (6%)		2 (4%)	
Renal Tubule, Dilatation	14 (28%)	14 (28%)	15 (31%)	9 (18%)
Renal Tubule, Hyperplasia		1 (2%)		
Renal Tubule, Pigmentation	1 (2%)		3 (6%)	
Transitional Epithelium, Hyperplasia	1 (2%)			
Urethra	(0)	(4)	(3)	(0)
Angiectasis		1 (25%)	1 (33%)	
Hemorrhage			1 (33%)	
Inflammation, Acute		2 (50%)	2 (67%)	
Necrosis		1 (25%)	1 (33%)	
Bulbourethral Gland, Cyst		1 (25%)		
Bulbourethral Gland, Hemorrhage			1 (33%)	
Bulbourethral Gland, Inflammation		1 (25%)		
Bulbourethral Gland, Necrosis		2 (50%)	1 (33%)	
Urinary Bladder	(50)	(49)	(48)	(48)
Fibrosis		1 (2%)		
Hemorrhage	2 (4%)	1 (2%)	1 (2%)	
Hyperplasia, Lymphoid			1 (2%)	
Inflammation, Acute	2 (4%)	1 (2%)	1 (2%)	
Inflammation, Chronic Active		1 (2%)	1 (2%)	
Necrosis	1 (2%)	3 (6%)	3 (6%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE MALE

0 MG/KG

3 MG/KG

30 MG/KG

100 MG/KG

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
--------------------	---------	---------	----------	-----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Accidentally Killed	1			
Dosing Accident			1	
Moribund Sacrifice	10	10	9	46
Natural Death	6	5	3	4
Survivors				
Terminal Sacrifice	33	35	37	
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Foreign Body			1 (2%)	
Inflammation, Granulomatous				1 (2%)
Inflammation, Acute			1 (2%)	
Inflammation, Chronic		1 (2%)		
Necrosis	1 (2%)			
Muscularis, Degeneration	1 (2%)	1 (2%)	2 (4%)	3 (6%)
Gallbladder	(44)	(44)	(47)	(45)
Intestine Large, Cecum	(46)	(45)	(47)	(47)
Intestine Large, Colon	(47)	(45)	(47)	(47)
Intestine Large, Rectum	(47)	(46)	(47)	(47)
Diverticulum			1 (2%)	
Edema		1 (2%)		
Intestine Small, Duodenum	(46)	(45)	(47)	(47)
Intestine Small, Ileum	(46)	(45)	(47)	(47)
Hyperplasia, Lymphoid	1 (2%)			
Ulcer	1 (2%)			
Intestine Small, Jejunum	(46)	(45)	(47)	(47)
Inflammation, Acute			1 (2%)	
Liver	(50)	(49)	(50)	(49)
Basophilic Focus	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Clear Cell Focus		3 (6%)	2 (4%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Eosinophilic Focus	3 (6%)	1 (2%)	15 (30%)	8 (16%)
Eosinophilic Focus, Multiple		1 (2%)	1 (2%)	7 (14%)
Fatty Change	18 (36%)	18 (37%)	39 (78%)	20 (41%)
Fibrosis	1 (2%)	1 (2%)		
Hematopoietic Cell Proliferation	13 (26%)	15 (31%)	8 (16%)	13 (27%)
Hemorrhage	4 (8%)	1 (2%)	4 (8%)	5 (10%)
Inflammation, Acute				1 (2%)
Inflammation, Chronic	32 (64%)	33 (67%)	34 (68%)	32 (65%)
Mixed Cell Focus		2 (4%)		1 (2%)
Necrosis, Focal	1 (2%)	1 (2%)	4 (8%)	3 (6%)
Tension Lipidosis	3 (6%)	2 (4%)	2 (4%)	
Centrilobular, Mineralization			1 (2%)	
Centrilobular, Necrosis			2 (4%)	
Centrilobular, Hepatocyte, Hypertrophy		7 (14%)	45 (90%)	47 (96%)
Hepatocyte, Cytoplasmic Alteration			1 (2%)	
Kupffer Cell, Pigmentation	3 (6%)	10 (20%)	24 (48%)	27 (55%)
Midzonal, Necrosis			1 (2%)	
Mesentery	(11)	(26)	(12)	(5)
Accessory Spleen		1 (4%)		
Cyst		1 (4%)		
Inflammation, Chronic		1 (4%)		
Inflammation, Chronic Active	1 (9%)			
Mineralization		1 (4%)		
Fat, Necrosis	10 (91%)	22 (85%)	12 (100%)	3 (60%)
Oral Mucosa	(0)	(1)	(0)	(0)
Pancreas	(50)	(48)	(50)	(50)
Atrophy	6 (12%)	8 (17%)	5 (10%)	
Cyst	1 (2%)	3 (6%)	3 (6%)	
Fibrosis		1 (2%)	1 (2%)	
Inflammation, Chronic	29 (58%)	31 (65%)	31 (62%)	22 (44%)
Inflammation, Chronic Active		1 (2%)		
Mineralization, Chronic			1 (2%)	
Necrosis	1 (2%)	1 (2%)		1 (2%)
Duct, Cyst				1 (2%)
Salivary Glands	(50)	(50)	(50)	(48)
Atrophy	1 (2%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Infiltration Cellular, Mononuclear Cell	32 (64%)	37 (74%)	30 (60%)	26 (54%)
Mineralization	1 (2%)	5 (10%)	5 (10%)	1 (2%)
Necrosis	1 (2%)			
Stomach, Forestomach	(50)	(50)	(50)	(49)
Angiectasis, Focal				1 (2%)
Cyst	1 (2%)		1 (2%)	
Edema	1 (2%)			
Erosion		1 (2%)	2 (4%)	3 (6%)
Hemorrhage	1 (2%)			
Infiltration Cellular, Mast Cell			1 (2%)	
Inflammation	5 (10%)	3 (6%)	5 (10%)	6 (12%)
Inflammation, Acute				1 (2%)
Inflammation, Chronic	2 (4%)			
Mineralization		1 (2%)		
Ulcer	5 (10%)	3 (6%)	1 (2%)	1 (2%)
Epithelium, Hyperplasia	9 (18%)	5 (10%)	6 (12%)	16 (33%)
Stomach, Glandular	(49)	(47)	(47)	(48)
Erosion	1 (2%)			1 (2%)
Inflammation, Acute	1 (2%)	1 (2%)	1 (2%)	
Mineralization	5 (10%)	6 (13%)	6 (13%)	1 (2%)
Ulcer		1 (2%)	1 (2%)	
Epithelium, Vacuolization Cytoplasmic	1 (2%)			
Glands, Ectasia, Focal	4 (8%)	3 (6%)	4 (9%)	1 (2%)

CARDIOVASCULAR SYSTEM

Blood Vessel	(47)	(49)	(50)	(49)
Inflammation	1 (2%)			
Mineralization	1 (2%)		1 (2%)	
Heart	(50)	(50)	(50)	(49)
Cardiomyopathy	4 (8%)	8 (16%)	5 (10%)	
Hemorrhage			1 (2%)	
Inflammation, Chronic		1 (2%)		
Mineralization	1 (2%)	4 (8%)	2 (4%)	1 (2%)
Necrosis, Multifocal			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thrombosis			1 (2%)	
Valve, Thrombosis	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(49)	(47)
Accessory Adrenal Cortical Nodule	5 (10%)	5 (10%)	1 (2%)	3 (6%)
Degeneration, Fatty	3 (6%)	2 (4%)	3 (6%)	
Hematopoietic Cell Proliferation		2 (4%)	2 (4%)	1 (2%)
Hemorrhage	1 (2%)			2 (4%)
Hyperplasia	1 (2%)		4 (8%)	
Hyperplasia, Focal		1 (2%)		
Hypertrophy, Focal	7 (14%)	4 (8%)	9 (18%)	2 (4%)
Hypertrophy, Diffuse			4 (8%)	8 (17%)
Capsule, Cyst				1 (2%)
Capsule, Hyperplasia	49 (98%)	50 (100%)	47 (96%)	47 (100%)
Adrenal Medulla	(49)	(50)	(48)	(48)
Hyperplasia	1 (2%)		1 (2%)	
Pigmentation		1 (2%)		
Islets, Pancreatic	(50)	(48)	(50)	(50)
Hyperplasia	3 (6%)	3 (6%)	2 (4%)	1 (2%)
Parathyroid Gland	(44)	(48)	(47)	(47)
Cyst	2 (5%)	1 (2%)	1 (2%)	
Hyperplasia			1 (2%)	
Pituitary Gland	(50)	(47)	(46)	(45)
Pars Distalis, Angiectasis		1 (2%)	1 (2%)	
Pars Distalis, Cyst	2 (4%)		1 (2%)	
Pars Distalis, Hyperplasia	9 (18%)	13 (28%)	13 (28%)	10 (22%)
Rathke's Cleft, Cyst	1 (2%)			1 (2%)
Thyroid Gland	(50)	(49)	(48)	(47)
Infiltration Cellular, Mononuclear Cell		1 (2%)		
Inflammation, Chronic	1 (2%)	1 (2%)		
Follicle, Cyst	2 (4%)	1 (2%)		
Follicle, Degeneration	34 (68%)	28 (57%)	26 (54%)	11 (23%)
Follicle, Degeneration, Focal		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Follicle, Hypertrophy	24 (48%)	31 (63%)	37 (77%)	42 (89%)
Follicular Cell, Hyperplasia				1 (2%)

GENERAL BODY SYSTEM

Peritoneum	(0)	(0)	(0)	(1)
Tissue NOS	(1)	(2)	(0)	(1)
Abscess, Chronic				1 (100%)
Fibrosis		1 (50%)		
Foreign Body				1 (100%)
Inflammation, Chronic		1 (50%)		
Mineralization		1 (50%)		
Fat, Fibrosis		1 (50%)		
Fat, Inflammation, Chronic Active		1 (50%)		
Fat, Necrosis		1 (50%)		

GENITAL SYSTEM

Clitoral Gland	(49)	(49)	(50)	(50)
Cyst	1 (2%)			
Inflammation, Acute	1 (2%)			
Inflammation, Chronic Active	5 (10%)	13 (27%)	8 (16%)	18 (36%)
Ovary	(48)	(49)	(50)	(48)
Abscess, Chronic Active	1 (2%)			
Angiectasis	1 (2%)		1 (2%)	
Atrophy				1 (2%)
Cyst	13 (27%)	13 (27%)	6 (12%)	7 (15%)
Thrombosis			1 (2%)	
Uterus	(50)	(50)	(50)	(49)
Angiectasis	1 (2%)			
Cyst	2 (4%)			
Edema	1 (2%)			
Hemorrhage	1 (2%)	2 (4%)		
Hyperplasia, Cystic	45 (90%)	47 (94%)	46 (92%)	43 (88%)
Inflammation, Histiocytic	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Inflammation, Acute	1 (2%)		1 (2%)	
Necrosis	1 (2%)		1 (2%)	
Thrombosis	1 (2%)			
Serosa, Cyst				1 (2%)
Vagina	(0)	(1)	(0)	(0)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(49)	(50)	(50)	(49)
Infiltration Cellular, Histiocyte	1 (2%)			
Myeloid Cell, Hyperplasia	1 (2%)	3 (6%)	1 (2%)	
Lymph Node	(9)	(17)	(12)	(4)
Ectasia	3 (33%)	6 (35%)	4 (33%)	
Hemorrhage	3 (33%)	5 (29%)	3 (25%)	
Hyperplasia, Lymphoid		2 (12%)		1 (25%)
Pigmentation	3 (33%)	5 (29%)	5 (42%)	
Iliac, Ectasia			1 (8%)	
Iliac, Hemorrhage		1 (6%)	1 (8%)	
Iliac, Hyperplasia, Lymphoid	1 (11%)		1 (8%)	
Iliac, Hyperplasia, Plasma Cell			1 (8%)	
Lumbar, Pigmentation			1 (8%)	
Pancreatic, Hyperplasia, Lymphoid		1 (6%)		
Renal, Hematopoietic Cell Proliferation		1 (6%)		
Renal, Hyperplasia, Lymphoid			1 (8%)	
Renal, Pigmentation		1 (6%)	1 (8%)	
Lymph Node, Mandibular	(48)	(50)	(50)	(45)
Atrophy	1 (2%)			
Ectasia	1 (2%)			
Fibrosis	1 (2%)			
Hematopoietic Cell Proliferation				1 (2%)
Hemorrhage				1 (2%)
Hyperplasia, Lymphoid	3 (6%)	3 (6%)	2 (4%)	
Hyperplasia, Plasma Cell	1 (2%)	1 (2%)		
Infiltration Cellular, Mast Cell			1 (2%)	
Inflammation, Chronic Active	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pigmentation	36 (75%)	39 (78%)	41 (82%)	38 (84%)
Lymph Node, Mesenteric	(48)	(45)	(49)	(48)
Atrophy	1 (2%)		1 (2%)	1 (2%)
Ectasia		1 (2%)	3 (6%)	
Hemorrhage		2 (4%)		
Hyperplasia, Lymphoid	1 (2%)	1 (2%)	1 (2%)	
Hyperplasia, Plasma Cell	1 (2%)			
Necrosis, Lymphoid				2 (4%)
Pigmentation				2 (4%)
Spleen	(50)	(47)	(48)	(48)
Accessory Spleen		1 (2%)		
Atrophy	1 (2%)			
Hematopoietic Cell Proliferation	15 (30%)	10 (21%)	11 (23%)	24 (50%)
Necrosis	1 (2%)			
Pigmentation	35 (70%)	26 (55%)	28 (58%)	31 (65%)
Lymphoid Follicle, Atrophy	2 (4%)	1 (2%)	3 (6%)	1 (2%)
Lymphoid Follicle, Hyperplasia	12 (24%)	20 (43%)	7 (15%)	21 (44%)
Lymphoid Follicle, Hyperplasia, Plasma Cell	1 (2%)			
Lymphoid Follicle, Hyperplasia, Focal	2 (4%)			
Thymus	(48)	(45)	(46)	(46)
Atrophy	25 (52%)	22 (49%)	26 (57%)	13 (28%)
Cyst	8 (17%)	6 (13%)	6 (13%)	2 (4%)
Hyperplasia, Lymphoid	16 (33%)	16 (36%)	9 (20%)	10 (22%)
Mineralization	1 (2%)			
Necrosis, Lymphoid	2 (4%)	1 (2%)	1 (2%)	

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Galactocele	30 (60%)	28 (56%)	32 (64%)	31 (62%)
Hyperplasia	3 (6%)		5 (10%)	
Inflammation, Chronic	1 (2%)	2 (4%)	3 (6%)	1 (2%)
Inflammation, Chronic Active			1 (2%)	1 (2%)
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	2 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Edema		2 (4%)	1 (2%)	
Fibrosis	1 (2%)		2 (4%)	
Foreign Body	1 (2%)	1 (2%)	1 (2%)	
Hemorrhage	1 (2%)	2 (4%)		
Hyperkeratosis	1 (2%)	1 (2%)		
Infiltration Cellular, Mast Cell		1 (2%)		
Inflammation, Granulomatous	1 (2%)	1 (2%)		
Inflammation, Acute	2 (4%)	4 (8%)	3 (6%)	
Inflammation, Chronic	6 (12%)	8 (16%)	10 (20%)	8 (16%)
Inflammation, Chronic Active	2 (4%)	2 (4%)	3 (6%)	2 (4%)
Mineralization		2 (4%)	2 (4%)	1 (2%)
Necrosis, Fatty, Focal				1 (2%)
Ulcer	4 (8%)	4 (8%)	6 (12%)	
Epidermis, Hyperplasia			1 (2%)	
Epidermis, Tail, Hyperkeratosis	1 (2%)		2 (4%)	
Epidermis, Tail, Hyperplasia	1 (2%)	4 (8%)	3 (6%)	
Hair Follicle, Atrophy, Focal				1 (2%)
Hair Follicle, Inflammation, Chronic Active				1 (2%)
Lip, Foreign Body		1 (2%)		
Lip, Inflammation, Chronic	1 (2%)	1 (2%)		
Lip, Inflammation, Chronic Active		1 (2%)		
Subcutaneous Tissue, Fibrosis		1 (2%)		

MUSCULOSKELETAL SYSTEM

Bone	(49)	(50)	(50)	(50)
Fibro-Osseous Lesion	43 (88%)	46 (92%)	49 (98%)	43 (86%)
Tail, Callus	1 (2%)		2 (4%)	1 (2%)
Tail, Developmental Malformation			1 (2%)	
Vertebra, Callus			1 (2%)	
Skeletal Muscle	(2)	(3)	(4)	(1)
Fibrosis			1 (25%)	
Hemorrhage			2 (50%)	
Inflammation, Chronic			1 (25%)	
Mineralization			1 (25%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Necrosis			1 (25%)	
Regeneration			1 (25%)	

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(49)
Compression	1 (2%)	2 (4%)	1 (2%)	
Developmental Malformation				1 (2%)
Hemorrhage	3 (6%)	1 (2%)	3 (6%)	1 (2%)
Infiltration Cellular, Mononuclear Cell	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Necrosis			1 (2%)	
Pigmentation			1 (2%)	
Meninges, Inflammation, Chronic	1 (2%)			
Peripheral Nerve	(1)	(1)	(1)	(1)
Degeneration	1 (100%)		1 (100%)	
Sciatic, Degeneration		1 (100%)		
Spinal Cord	(1)	(1)	(3)	(1)
Degeneration			2 (67%)	

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)
Congestion	2 (4%)	1 (2%)	1 (2%)	
Cyst			1 (2%)	
Edema				1 (2%)
Fibrosis	1 (2%)			
Foreign Body			1 (2%)	
Hemorrhage	12 (24%)	3 (6%)	1 (2%)	7 (14%)
Infiltration Cellular, Histiocyte	4 (8%)	2 (4%)	2 (4%)	1 (2%)
Inflammation, Granulomatous				1 (2%)
Inflammation, Acute			1 (2%)	
Metaplasia, Osseous	2 (4%)			2 (4%)
Mineralization	3 (6%)	2 (4%)	3 (6%)	
Thrombosis	1 (2%)		1 (2%)	1 (2%)
Alveolar Epithelium, Hyperplasia			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Alveolus, Infiltration Cellular, Histiocyte				1 (2%)
Nose	(50)	(50)	(50)	(48)
Foreign Body	4 (8%)	3 (6%)	3 (6%)	3 (6%)
Inflammation, Acute	6 (12%)	6 (12%)	4 (8%)	10 (21%)
Mineralization				1 (2%)
Pleura	(0)	(0)	(1)	(0)
Inflammation, Suppurative			1 (100%)	
Trachea	(50)	(50)	(50)	(47)

SPECIAL SENSES SYSTEM

Eye	(47)	(45)	(47)	(48)
Atrophy		1 (2%)		
Cornea, Inflammation, Acute			1 (2%)	
Harderian Gland	(50)	(49)	(50)	(49)
Hyperplasia	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Inflammation, Chronic		1 (2%)		

URINARY SYSTEM

Kidney	(50)	(50)	(49)	(48)
Infarct			1 (2%)	1 (2%)
Infiltration Cellular, Mononuclear Cell	38 (76%)	44 (88%)	43 (88%)	45 (94%)
Metaplasia, Osseous			1 (2%)	1 (2%)
Mineralization	7 (14%)	5 (10%)	5 (10%)	1 (2%)
Nephropathy	14 (28%)	9 (18%)	9 (18%)	3 (6%)
Artery, Inflammation, Chronic	1 (2%)			
Interstitial, Inflammation, Chronic	1 (2%)			2 (4%)
Papilla, Necrosis		2 (4%)		
Pelvis, Inflammation, Chronic				1 (2%)
Renal Tubule, Accumulation, Hyaline Droplet	2 (4%)	1 (2%)		1 (2%)
Renal Tubule, Atrophy		1 (2%)	1 (2%)	
Renal Tubule, Cyst				1 (2%)
Renal Tubule, Degeneration		1 (2%)	1 (2%)	
Renal Tubule, Dilatation	31 (62%)	23 (46%)	34 (69%)	43 (90%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:43

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Renal Tubule, Necrosis			1 (2%)	
Renal Tubule, Regeneration			1 (2%)	
Renal Tubule, Vacuolization Cytoplasmic			1 (2%)	
Urinary Bladder	(49)	(50)	(49)	(48)
Hyperplasia, Lymphoid	1 (2%)			

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion